Atara Biotherapeutics Inc. reported its latest financial results, missing analyst expectations on both the top and bottom lines. The company posted an earnings miss of $0.10 per share, while revenue for the period also fell short of consensus estimates.
Financial details and guidance figures from the report were limited following the announcement, but the miss highlights ongoing headwinds for the biotechnology firm as it navigates its clinical pipeline and commercial strategy.
